Redenlab is supporting a new long term open label extension study in Friedreich ataxia

Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial for a medium sized sponsor. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.

Friedreich ataxia is a multisystem neurodegenerative disorder and the most common of the hereditary ataxia syndromes, with a prevalence of 0.5–3/100 000 individuals of western European lineage. It is caused by a triplet repeat expansion in the FXN gene, which leads to reduced frataxin, a mitochondrial protein important for iron metabolism. There is currently no treatment proven to alter its natural course. Symptoms typically present at 10–15 years of age but can be earlier or considerably later, and patients are usually wheelchair dependent within 10–15 years of disease onset. Other deficits include dysarthria and dysphagia, progressive limb and gait ataxia, optic and auditory neuropathy, scoliosis, and cardiomyopathy. For a patient perspective, read here:

Related Post

  • Posted on 25 January, 2024
    MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
    • Posted on 24 October, 2023
      Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to significant changes...
      • Posted on 24 October, 2023
        Friedreich ataxia (FA) is an inherited, multisystem neurodegenerative disease that results in profound changes to speech, swallowing, balance, walking, cardiac...